HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients
Summary
& SHANGHAI & PARIS--(BUSINESS WIRE)--Scientists at HiFiBiO Therapeutics have generated preclinical data packages for novel monoclonal antibodies that demonstrate favorable clinical development profiles as new cancer immunotherapeutic options. “We are pleased to have the opportunity to present our work to the oncology research community at AACR and to share our innovative approach to transform the drug discovery and development paradigm by combining a deep understanding of immune-modulation with a world-leading single-cell platform and integrated analytics. By applying this approach over the past two and a half years, we have built a sustainable pipeline with high-quality candidates moving rapidly towards clinical studies,” said Liang Schweizer, PhD, President and CEO of HiFiBiO Therapeutics. Our pipeline focuses on targets with roles on multiple immune cell types, and our development strategy hinges on combining candidates with novel biomarkers to ensure a higher probability of clinical success,” commented Francisco Adrian, Senior Vice President of Global Research, HiFiBiO Therapeutics. Using this approach, we should be able to stratify patients using their profiled genotype and phenotype, which predict sensitivity or resistance to treatment with our antibody candidates,” said Andreas Raue, Senior Director of Drug Intelligent Science, HiFiBiO Therapeutics.